OKYO Pharma (FRA:OK10) Marketable Securities: €5.19 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OK10 OKYO Pharma Ltd FRA:OK10
24 GF Score
Price €1.36
! 2 Warning Signs
View Full Analysis

What is OKYO Pharma Marketable Securities?

OKYO Pharma FRA:OK10 24 Marketable Securities is €5.19 Mil as of Mar. 2026. GuruFocus rates FRA:OK10 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. OKYO Pharma's Marketable Securities for the quarter that ended in Mar. 2026 was €5.19 Mil.

OKYO Pharma's annual Marketable Securities stayed the same from Mar. 2024 (€0.00 Mil) to Mar. 2025 (€0.00 Mil) but then increased from Mar. 2025 (€0.00 Mil) to Mar. 2026 (€5.19 Mil).

OKYO Pharma  (FRA:OK10) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

OKYO Pharma Marketable Securities Related Terms

OKYO Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Marketable Securities Chart

OKYO Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.19

OKYO Pharma Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.19
FRA:OK10
24GF Score
OKYO Pharma Ltd FRA:OK10
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €5.19 Mil mean?
OKYO Pharma (FRA:OK10) has a Marketable Securities of €5.19 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on OKYO Pharma and its competitors.
Is OKYO Pharma's Marketable Securities too high?
OKYO Pharma's current Marketable Securities is €5.19 Mil. Overall, OKYO Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Marketable Securities compare to ALPS and CGTX?
OKYO Pharma's Marketable Securities of €5.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current Marketable Securities is €5.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current Marketable Securities of €5.19 Mil. The current Marketable Securities is €5.19 Mil. OKYO Pharma's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current Marketable Securities is €5.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score

Get the complete analysis for FRA:OK10

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price